Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruconest for Acute Attacks in Pediatric Hereditary Angioedema
NCT01359969Phase 2Completed
- Sponsor
- Pharming Group
- Start
- Jan 2012
- Primary completion
- Jul 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of c1-esterase inhibitor in hereditary angioedema (HAE), sponsored by Pharming Group. Primary endpoint: Time to Beginning of Relief Based on Visual Analogue Scale (VAS) at 24 hours. Started Jan 2012; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT01359969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01359969.